Zacks Investment Research upgraded shares of Histogenics Corporation (NASDAQ:HSGX) from a hold rating to a buy rating in a report released on Monday morning. Zacks Investment Research currently has $2.25 target price on the biotechnology company’s stock.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Several other research analysts have also recently issued reports on the stock. ValuEngine cut shares of Histogenics Corporation from a sell rating to a strong sell rating in a report on Monday, August 14th. Canaccord Genuity reaffirmed a buy rating and issued a $4.00 target price on shares of Histogenics Corporation in a report on Friday, August 11th. Finally, HC Wainwright set a $4.00 target price on shares of Histogenics Corporation and gave the stock a buy rating in a report on Friday, August 11th.
Shares of Histogenics Corporation (NASDAQ:HSGX) opened at 2.00 on Monday. The stock’s market cap is $44.98 million. The firm has a 50-day moving average of $1.86 and a 200 day moving average of $1.77. Histogenics Corporation has a 1-year low of $1.45 and a 1-year high of $3.56.
Histogenics Corporation (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. During the same quarter in the prior year, the business posted ($0.61) EPS. Equities research analysts forecast that Histogenics Corporation will post ($1.09) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Histogenics Corporation (HSGX) Raised to Buy at Zacks Investment Research” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/21/histogenics-corporation-hsgx-raised-to-buy-at-zacks-investment-research.html.
An institutional investor recently raised its position in Histogenics Corporation stock. Sabby Management LLC grew its position in Histogenics Corporation (NASDAQ:HSGX) by 15.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,095,422 shares of the biotechnology company’s stock after buying an additional 150,531 shares during the period. Sabby Management LLC owned approximately 5.31% of Histogenics Corporation worth $1,895,000 as of its most recent SEC filing. 50.08% of the stock is currently owned by institutional investors.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.